Why Seaport Therapeutics, Inc.’s (SPTX) Stock Is Down 5.49%
As of Friday, August 28, Seaport Therapeutics, Inc.’s SPTX share price has dipped by 5.49%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company’s lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.
Commentary & Analysis
Why Seaport Therapeutics, Inc.’s (SPTX) Stock Is Up 8.80%
As of Wednesday, August 19, Seaport Therapeutics, Inc.’s SPTX share price has surged by 8.80%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Seaport Therapeutics, Inc.’s (SPTX) Stock Is Up 5.50%
As of Wednesday, August 12, Seaport Therapeutics, Inc.’s SPTX share price has surged by 5.50%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Seaport Therapeutics, Inc.’s (SPTX) Stock Is Up 5.07%
As of Monday, July 27, Seaport Therapeutics, Inc.’s SPTX share price has surged by 5.07%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Seaport Therapeutics, Inc.’s (SPTX) Stock Is Down 5.79%
As of Monday, July 13, Seaport Therapeutics, Inc.’s SPTX share price has dipped by 5.79%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | SPTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,330.8 | $674.5 | 48% |
|
| Shares Out (Mil) | 35.2 | 43.5 | 40% |
|
| Institutional Ownership | 89.9% | 84.6% | 57% |
|
| Float (Mil) | 18.4 | 47.3 | 27% |
|
| Beta | na | 0.71 | na |
|
| Avg Daily Volume (000s) | 119 | 290 | 39% |
|
| Price Change (52-week) |
na | 69.3% | na |
|
| Growth | SPTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.566) | ($5.900) | ($2.573) | |
| Month Ago EPS | ($0.562) | ($6.240) | ($2.577) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | ($0.553) | ($3.253) | ($2.420) | |
| Year/Year Chg | (68.1%) | (41.3%) | (71.3%) | |
| Financials | SPTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($135) | ($11) | 9% |
|
| EPS (TTM) | ($8.500) | ($0.700) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($89) | ($6) | 7% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $3 | $6 | 22% |
|
| Enterprise Value (Q1) (Mil) | $996 | $536 | 40% |
|
| Valuation | SPTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.15 | 2.80 | 66% |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SPTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.1% | na |
|
| Net Margin | na | (1.4%) | na |
|
| ROA | (61.0%) | (24.1%) | 10% |
|
| ROE | (63.7%) | (21.0%) | 13% |
|
| Liabilities to Assets | 4.3% | 32.3% | 2% |
|
| F-Score | 1 | 3 | na |
|
Seaport Therapeutics, Inc. did not pass any screens on 9/4/2026.
